Abbvie Inc
NYSE:ABBV
Abbvie Inc
Gross Profit
Abbvie Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$21.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Moderna Inc
NASDAQ:MRNA
|
Gross Profit
$2.2B
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
27%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
19%
|
See Also
What is Abbvie Inc's Gross Profit?
Gross Profit
36.1B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Gross Profit amounts to 36.1B USD.
What is Abbvie Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
10%
Over the last year, the Gross Profit growth was -13%. The average annual Gross Profit growth rates for Abbvie Inc have been 6% over the past three years , 7% over the past five years , and 10% over the past ten years .